A

n inhaled antibiotic from Insmed (INSM) successfully treated patients with a rare lung disease caused by a bacterial infection, according to results from a phase 3 clinical trial reported Tuesday.

Based on the findings from the phase 3 study, Insmed said it plans to seek accelerated approval from the FDA for the inhaled antibiotic, known as ALIS, as a new treatment for adults with nontuberculous mycobacterial (NTM) lung disease.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have Interstatial Pulmonary Fibrosis exhibiting by lots of scaring which is random in its presentation. Would this medication allow my O2 intake to pass more easily into my blood stream ??

    • William, I am not an MD, but I can tell you that the late Jerry Lewis had interstitial pulmonary fibrosis, for which he received high dose steroids. It’s a tough treatment but was helpful in his case.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X